<DOC>
	<DOCNO>NCT02404558</DOCNO>
	<brief_summary>Primary Objective : To describe safety tolerability , include laboratory abnormality follow single dose sarilumab tocilizumab administer subcutaneously ( SC ) monotherapy Japanese patient rheumatoid arthritis ( RA ) . Secondary Objectives : To describe laboratory abnormality ( absolute neutrophil count [ ANC ] , platelet count , total cholesterol , high-density lipoprotein [ HDL ] cholesterol , low-density lipoprotein [ LDL ] cholesterol , liver function test [ LFTs ] ) follow single dose sarilumab tocilizumab administer SC monotherapy Japanese patient RA . To describe pharmacokinetics ( PK ) sarilumab tocilizumab .</brief_summary>
	<brief_title>Single-dose Study Describe Safety Sarilumab Tocilizumab Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Total study duration ( per patient ) expect 71 day include screening ( 3 28 day dose ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion : Patients rheumatoid arthritis ( RA ) define American College Rheumatology ( ACR ) /European League Rheumatism ( EULAR ) 2010 Rheumatoid Arthritis Classification Criteria . ACR Class IIII functional status , base 1991 revised criterion . Exclusion criterion : Patients le 20 year age . Prior treatment biologic antiinterleukin6 ( antiIL6 ) interleukin6 receptor ( IL6R ) antagonist . Any parenteral intraarticular glucocorticoid injection within 4 week prior randomization . Treatment prednisone high 10 mg equivalent per day , change dosage within 4 week prior randomization . Treatment diseasemodifying antirheumatic drug ( DMARDs ) , immunosuppressive agent , tumor necrosis factor ( TNF ) antagonists RAdirected biologic agent within certain amount time prior randomization . Participation clinical research study evaluate investigational drug therapy within 5 halflives 60 day screen visit , whichever longer . Active suspect tuberculosis ( TB ) high risk contract TB . Fever , chronic , persistent , recur infection ( ) require active treatment . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>